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Today, there is increasing evidence that PPARγ agonists, including thiazolidinediones (TDZs) and nonthiazolidinediones, block
the motility and invasiveness of glioma cells and other highly migratory tumor entities. However, the mechanism(s) by which
PPARγ activators mediate their antimigratory and anti-invasive properties remains elusive. This letter gives a short review on
the debate and adds to the current knowledge by applying a PPARγ inactive derivative of the TDZ troglitazone (Rezulin) which
potently counteracts experimental glioma progression in a PPARγ independent manner.
Copyright © 2008 Sebastian Seufert et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Gliomasarethemostcommonprimarytumorsinthecentral
nervous system, with glioblastomas as the most malignant
entity [1]. Despite multimodal therapy regimens including
neurosurgical resection, radio- and polychemotherapy, the
prognosis of glioma patients remains poor. Less than 3% of
aﬀected patients survive more than ﬁve years after diagnosis
[2]. Rapid proliferation, tumor-induced neurodegeneration,
and brain edema [3]a sw e l la sd i ﬀuse brain invasion are
pathological hallmarks of these tumors and are likely to
determine unfavorable prognosis. Because local invasion
of neoplastic cells into the surrounding brain is perhaps
the most important aspect in the biology of gliomas that
preclude successful treatment, pharmacological inhibition of
glioma cell migration and brain invasion is considered as a
highly promising strategy for adjuvant glioma therapy.
Today, there is increasing evidence that PPARγ agonists,
including thiazolidinediones (TDZs) and nonthiazolidine-
diones, block the motility and invasiveness of glioma cells
and other highly migratory tumor entities. GW7845, an
investigational non-TDZ PPARγ ligand, binds and activates
human PPARγ at low nanomolar concentrations and thus
possesses a higher potency than TDZs such as pioglitazone
(Actos), troglitazone (Rezulin), rosiglitazone (Avandia), and
the experimental PPARγ agonist ciglitazone, respectively,
which require submicromolar doses [4]. Grommes et al.
[5] demonstrated that 30μM concentrations of GW7845
reduced the viability of rat (C6) and human glioma cells
(U-87 MG, A172), which could be attributed to a G1 cell
cycle arrest and increased cell death. Besides its antiprolif-
erative and cytotoxic properties, the authors demonstrated
for the ﬁrst time that GW7845 counteracts migration
and invasion of C6 rat glioma cells in vitro (spheroid
outgrowth, Boyden chamber assay). A subsequent study
revealed that the FDA-approved TDZ pioglitazone exhibits
antigliomapropertiessimilartoGW7845[6].AlikeGW7845,
micromolar doses of pioglitazone (30μM) counteract C6 rat
glioma cell invasiveness in vitro (Boyden chamber assay).
In this study, Grommes et al. [6] demonstrated profound
in vivo antiglioma properties of pioglitazone. Following
C6 glioma cell implantation into the striata of adult rats,
oral or intracerebral drug application eﬀectively deceler-
ated glioma progression, resulting in an improved clinical2 PPAR Research
outcome and 80% reduction of tumor volume at 3 weeks
after tumor implantation. Immunohistochemical analyses of
pioglitazone-treated animals revealed that protein levels of
MMP-9 (matrix metalloproteinase 9), which has shown to
be intimately involved in glioma migration and invasion
[7], were substantially reduced in the bulk tumor and the
tumor margins. However, the data regarding the antiglioma
properties of pioglitazone are somewhat contradictory in a
mouse glioma model (GL261 glioma cells, C57Bl/6 mice).
Grommes et al. demonstrated that oral application of
pioglitazone increased the number of surviving animals
after 30 days of treatment. By employing the same model,
Spagnolo and coworkers observed no eﬀect on survival
following oral drug application, while intracerebral injection
of pioglitazone increased the mean survival time [8]. We
have recently shown that the TDZ troglitazone reduces
the viability and proliferation of rat (F98), mouse (SMA-
560), and human (U-87 MG) glioma cells slightly but
signiﬁcantly more potent than the remaining TZDs tested
(troglitazone > pioglitazone > rosiglitazone > ciglitazone)
[9]. By employing an ex vivo glioma invasion model [10],
troglitazoneeﬀectivelyblockedgliomaprogressionandbrain
invasion and consistent with the in vitro data presented by
Grommes and coworkers, we conﬁrmed that troglitazone
(30μM) antagonized rat F98 glioma cell migration (scratch
wound healing, Boyden chamber assay).
Inhibition of cell motility and invasiveness by PPARγ
activators has also been described for other neoplastic cells
a n dt h u sa p p e a r sn o tt ob er e s t r i c t e dt og l i o m a .L i ue t
al. [14] showed that GW7845 (5μM) as well as the FDA-
approved TDZs pioglitazone and rosiglitazone (both 25μM)
inhibits the invasive properties of human MDA-MB-231
breast cancer cells. In this study, treatment with PPARγ
agonists was associated with increased tissue inhibitor of
matrix metalloproteinase 1 (TIMP-1) mRNA and protein
levels, which are likely to contribute to the anti-invasive
eﬀects observed. Recently, Yang et al. [15] demonstrated that
troglitazone (10–30μM) inhibits migration and invasiveness
of a human ovarian carcinoma ES-2 cells. Anti-invasive
propertieswerealsoshownfortheTDZciglitazone,although
with a lower potency. Extended analyses by Yang et al.
revealed that troglitazone (20μM) inhibits focal adhesion
formation associated with reduced focal adhesion kinase
(FAK) activity. FAK, an ubiquitously expressed nonrecep-
tor tyrosine kinase, has shown to be a vitally important
regulator of cancer cell migration and invasion. FAK is
highly expressed in many tumor entities and activated by
autophosphorylation[16],whichhasshowntobereducedby
more than 80% in troglitazone-treated ES-2 cells [15]. Based
on these data, the authors concluded that troglitazone may
inhibit ES-2 cell migration and invasion by preventing FAK
activation. Concordantly, inhibition of FAK kinase activity
by the investigational small molecule TAE226 reduced the
invasive properties of human U-87 MG, U251, and LN18
glioma cells by more than 50% [17], suggesting that FAK
activation decisively promotes migration and invasion also
of glioma cells. In all, these data demonstrate that PPARγ
activators belonging to diﬀerent chemical classes eﬀectively
diminish glioma progression in vitro, ex vivo, and in vivo
[5, 6, 9], which occurs at least in part by the inhibition of
glioma cell migration and invasiveness.
Given the fact that cancer cell migration and invasion
are highly complex processes [18], the mechanism(s) by
which PPARγ agonists exert their antimigratory and anti-
invasive properties requires further investigation. Besides
MMP-9, TIMP-1, and FAK, which have been shown to
be involved in the antimigratory activities of PPARγ ago-
nists, we recently demonstrated that already low doses of
troglitazone block transforming growth factor beta (TGF-
β) release [9], a cytokine which plays a pivotal role in
glioma cell motility [19]. Several in vitro studies revealed
that exogenously added TGF-β1 and TGF-β2 elicit a strong
stimulation of migration in a variety of glioma cells [20–
23], while TGF-β gene silencing has shown to reduce
glioma cell motility and invasiveness [24]. In agreement
with these ﬁndings, inhibition of TGF-β signaling by the
investigational type I TGF-β receptor antagonist, SB-431542
reduced the invasive properties of human D-54 MG and
rat F98 glioma cells by approximately 70% [9, 25]. The
role of TGF-β as molecular target for glioma therapy has
been facilitated by studies using surgically resected glioma
tissues, which revealed an intriguing correlation between
tumor grade and the expression of TGF-β ligands and their
correspondingreceptorsIandII.High-gradegliomasexpress
high levels of TGF-βRI, TGF-βRII, and TGF-β ligands, while
the expression levels of these molecules have been shown to
be weak in low-grade gliomas and normal brain tissue [26–
28]. A comprehensive transcriptome-wide study by Demuth
et al. [29] using 111 glial tumor samples and 24 normal
brainspecimensidentiﬁedtheTGF-βsignalingpathwaytobe
predominantly enriched in glial tumors compared to normal
brain. In all, these data implicate that glioma cells release
TGF-β ligands at high doses and fortify their promigratory
and proinvasive properties in an autocrine manner, thus
promoting glioma progression. Given the fact that 10μM
doses of troglitazone allay TGF-β release of glioma cells
(F98, SMA-560, U-87 MG) by more than 50% [9], we
hypothesized that the abrogation of glioma cell motility and
invasiveness by troglitazone and other PPARγ activators is
primarily driven by the inhibition of TGF-β signaling and
thus,troglitazoneandrelatedcompoundsmaybeconsidered
for adjuvant glioma therapy to counteract TGF-β-mediated
brain invasion.
However, the mechanism(s) by which PPARγ activators
mediate their antimigratory and anti-invasive properties
remains elusive. We have shown that PPARγ inhibition by
the investigational antagonist GW9662, either alone or in
combinationwithtroglitazone,doesnotaﬀectratF98glioma
cell invasiveness in a Boyden chamber assay, suggesting
that the eﬀects observed are not mediated by PPARγ
[9]. Simultaneously, Yang and coworkers [15] have shown
that PPARγ knockdown by siRNA did not counteract the
anti-invasive features of troglitazone using human ovarian
carcinoma ES-2 cells, underscoring the idea that the PPARγ
agonists counteract cancer cell migration by a yet unknown
oﬀ-target activity. To validate these preliminary ﬁndings,
we analyzed the eﬀects of a troglitazone derivative, Δ2-
troglitazone, which has been shown to be PPARγ-inactiveSebastian Seufert et al. 3
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Figure 1: Troglitazone (TRO) and the PPARγ inactive Δ2-troglitazone (Δ2-TRO) reduce glioma cell viability and TGF-β1 release. Δ2-TRO was
synthesizedaspreviouslydescribedin[11].(a),(c)Concentration-dependentinhibitionofgliomacellviabilitybyTRO(a)orΔ2-TRO(c)in
the indicated cell lines are given as mean ± SEM percentage relative to time- and solvent-matched controls. Cell viability assays (MTT assay,
96 hours) were performed as described earlier [12, 13]. Inhibitory concentrations IC50 and IC90, deﬁned as concentrations shown to inhibit
tumor cell viability by 50% or 90%, respectively, were determined by nonlinear regression data analysis: TRO: F98 (62μM, 166μM), SMA-
560 (26μM, 407μM), U-87 MG (120μM, 324μM), and U-373 MG (123μM, 331μM); Δ2-TRO: F98 (46μM, 95μM), SMA-560 (23μM,
93μM), U-87 MG (78μM, 132μM), and U-373 MG (71μM, 126μM). Troglitazone and the PPARγ inactive Δ2-troglitazone reduce TGF-β1
release at low micromolar doses: (b), (d) quantiﬁcation of TGF-β1 release by F98, SMA-560, U87-MG, and U-373 MG glioma cell culture
supernatants following TRO (b) or Δ2-TRO (d) treatment for 48 hours. TGF-β1 p r o t e i nl e v e l si ng l i o m ac e l lc u l t u r es u p e r n a t a n t sw e r e
determinedasdescribedin[9]usingthemouse/rat/porcine/canineorthehumanquantikineTGF-β1 ELISAKit(R&DSystems,Minneapolis,
Minn, USA), respectively. Each experiment was repeated at least 3 times (n ≥ 3). Drug concentrations shown to inhibit TGF-β1 release by
50% or 90%, respectively, were determined by nonlinear regression data analysis: TRO: F98 (7μM, 11μM), SMA-560 (8μM, 15μM), U-87
MG (8μM, 28μM), and U-373 MG (10μM, 30μM); Δ2-TRO:F98 (3μM, 5μM), SMA-560 (3μM, 8μM), U-87 MG (4μM, 14μM), and
U-373 MG (4μM, 14μM). Δ2-Troglitazone displays higher potencies than troglitazone. Using IC90 concentrations of Δ2-TRO and equimolar
concentrations of TRO, the PPARγ inactive Δ2-TRO displays a signiﬁcantly stronger eﬀect in both experimental paradigms (∗∗∗ = P<. 001,
t-test) (e), (f).4 PPAR Research
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Figure 2: The PPARγ inactive Δ 2-troglitazone (Δ2-TRO) inhibits glioma cell migration. The glioma cell migration assay (Boyden chamber;
QCM-FNMigrationAssay,Chemicon,Temecula,Calif,USA)wasperformedasdescribedrecently[9].Brieﬂy,F98ratgliomacells,pretreated
with the test compound or solvent for 24 hours, were transferred into each Boyden chamber. After 24 hours of incubation, cells which
migrated through the ﬁbronectin-coated chamber membranes (8 micron pore diameter) were quantiﬁed according to the manufacturer’s
protocol. Experiments were repeated 3 times (n = 3). (∗∗ = P<. 01; ∗∗∗ = P<. 001; t-test). Right panel: representative microphotographs of
F98 glioma cells which migrated though the ﬁbronectin-coated chamber membranes after treatment with Δ2-TRO (20μM) or solvent only.
[11, 31, 32]. In case the antiglioma properties of troglitazone
are solely or predominantly due to PPARγ activation, Δ2-
troglitazone should display no or a considerably lower
inhibitory potency on glioma cell viability than troglitazone.
Initially, concentration-dependent inhibition of glioma cell
viabilitybytroglitazoneandΔ2-troglitazonewasinvestigated
using glioma cell lines derived from mouse (SMA-560), rat
(F98), and human (U-87 MG, U-373 MG). As shown by
MTT assay, both compounds inhibited glioma cell growth
in a concentration-dependent manner with similar poten-
cies (Figures 1(a), 1(c)). Even though numerous PPARγ-
dependent mechanisms have been identiﬁed (for review see
Tatenhorst et al., this issue), these data suggest that PPARγ
activation is not an imperative prerequisite for the inhibition
of glioma cell viability in vitro, which is in line with previous
studies using human PC-3 and LNCaP prostate cancer and
humanA549lungcarcinomacells[11,31].Next,weanalyzed
the reduction of glioma cell viability using IC90 doses of
Δ2-troglitazone and equimolar doses of troglitazone. In all
four cell lines tested, Δ2-troglitazone displays a slightly but
signiﬁcantly higher potency compared with troglitazone.
However, with IC90 doses ranging from 93μM (SMA-560) to
132μM (U-87 MG), the antiproliferative properties of Δ2-
troglitazone can be regarded as moderate.
Next, we analyzed the eﬀects of troglitazone and Δ2-
troglitazone on TGF-β release by glioma cells. Hjelmeland
et al. [25] have shown that secretion of activated TGF-β1
is a common attribute of glioma cells (U-87 MG, U-373
MG, D-54 MG, D-270 MG, D-423 MG, D-538 MG), while
simultaneous release of TGF-β2 was found only sporadi-
cally (D-54 MG, U-373 MG, D-423 MG). In accordance
with these ﬁndings, quantiﬁcation of TGF-β1 and TGF-β2
transcript levels by real-time PCR revealed that U-373 MG
and SMA-560 glioma cells express both TGF-β1 and TGF-
β2,r e s p e c t i v e l y ,w h i l eT G F - β1 is clearly the predominant
isoform in F98 and U-87 MG glioma cells (data not shown).
Repeated quantiﬁcation (n ≥ 7) of absolute TGF-β1 levels
following cultivation of glioma cells for 48 hours in serum-
free medium revealed that all cell lines investigated secrete
TGF-β1 (F98:8.45±1.59ng/mL;SMA-560:2.7±0.54ng/mL;
U-87MG:2.55±0.68ng/mL,U-373MG:0.43±0.08ng/mL),
while both troglitazone and Δ2-troglitazone inhibit TGF-β1
release in a dose-dependent manner (Figures 1(b), 1(d)).
The ﬁnding that Δ2-troglitazone counteracts TGF-β1 release
indicates that this eﬀect is not PPARγ dependent. Again,
Δ2-troglitazone displays a signiﬁcantly higher potency as
compared with troglitazone (Figure 1(f)). In case of Δ2-
troglitazone, 90% inhibition of TGF-β1 release was found
at concentrations ranging from 5μM (F98) to 14μM (U-87
MG,U-373MG),whereastroglitazonerequired11μM(F98)
to 30μM (U-373 MG) to achieve the same eﬀects. Strikingly,
troglitazone as well as Δ2-troglitazone is approximately 10
fold more potent inhibitors of TGF-β1 release than of glioma
cell proliferation, suggesting that both eﬀects may not be
essentially interlinked.
In agreement with the ﬁnding that TGF-β1 promotes
glioma cell migration and brain invasion, treatment of
glioma cells with micromolar doses of Δ2-troglitazone eﬀec-
tively blocks their migrative properties (Figure 2). Already
10μMd o s e so fΔ2-troglitazone inhibit F98 glioma cell
migration in a Boyden chamber assay, while migration was
completely suppressed at 20μM. An intriguing question
is whether inhibition of glioma cell migration alone is
suﬃcient to counteract glioma progression. To address
this issue we employed rat organotypic hippocampal brain
slice cultures (OHSCs) to monitor glioma progression and
brain invasion in the organotypic brain environment [12].
Here, eGFP-labelled F98 glioma cells were implanted into
the entorhinal cortex of OHSCs (Figure 3(a)). The tumor
inﬁltration area was quantiﬁed up to 12 days by ﬂuorescence
microscopy. A continuous increase of the bulk tumor mass
was observed in solvent-matched control experiments at
all time periods. 12 days after glioma cell implantation,
the tumor inﬁltration area increased approximately 4.5 fold
compared tothe initial tumorsize atday 1 afterimplantation
(Figures 3(b), 3(c)). In contrast, the tumor inﬁltration sizeSebastian Seufert et al. 5
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Figure 3: Δ2-Troglitazone inhibits glioma progression in an organotypic glioma transplantation model. (a) Organotypic hippocampal glioma
invasion assay was performed as described earlier [10, 12, 30]. In brief, enhanced green ﬂuorescent protein (eGFP) positive F98 rat glioma
cells were transplanted into the entorhinal cortex of organotypic rat brain slice cultures one day after preparation. DAI = days after
implantation. DG = dentate gyrus. EC = entorhinal cortex. (b) Tumor progression was monitored by ﬂuorescent microscopy over the
time course of 12 days. Quantiﬁcation of the tumor inﬁltration area at day 1 to day 12 after transplantation derived from 3 independent
experiments is shown. For each experiment, the tumor inﬁltration area at DAI 1 was deﬁned as 100%. Data are given as mean ± SD
percentage. At DAI 12, the tumor inﬁltration area signiﬁcantly increased to 448 ± 71 % (P = .002, t-test) in solvent-matched controls but
remained unchanged following Δ2-TRO treatment (75 ± 22 %; P = .18, t-test). Starting from DAI 2, diﬀerences in tumor progression
(TRO versus Δ2-TRO) reached statistical signiﬁcance (P<. 01, t-test) (c) A continuous increase of the bulk tumor masses was observed in
solvent-matched controls while 10μM concentrations of Δ2-TRO eﬀectively blocked tumor progression. Right column: magniﬁcation of the
indicated border area between bulk tumor mass and rat brain tissue. In controls, F98 glioma cells have diﬀusely migrated into the adjacent
brain parenchyma, while a sharp tumor border was observed following Δ2-TRO treatment (scale bar: 200μm).
remained stable over the period of 12 days after treatment
with 10μM Δ2-troglitazone. This ﬁnding indicates that Δ2-
troglitazone is not able to reduce existing tumor masses,
but eﬀectively inhibits tumor progression and brain invasion
in an organotypic environment. Given the fact that 10μM
doses of Δ2-troglitazone signiﬁcantly aﬀect TGF-β1 release
(Figure 1(d)) and glioma cell motility (Figure 2)b u tn o t
glioma cell viability (Figure 1(c)), these data suggest that
glioma cell migration is an essential requirement for glioma
progression in a system closely resembling extracellular
matrix environment present in the brain.
TGF-β antagonismisconsideredasatherapeuticstrategy
including the development of antisense regimens, inhibition
of pro-TGF-β processing, scavenging of TGF-β by the TGF-
β-binding proteoglycan decorin, and blocking of TGF-β
receptor I kinase activity [33]. The ﬁnding that troglitazone
and its derivative Δ2-troglitazone eﬀectively inhibit TGF-
β release suggests readily available PPARγ activators and
structurally related PPARγ inactive compounds as candidate
drugs for adjuvant glioma therapy. Besides its promigratory
and proinvasive activities, TGF-β is considered as one of the
most potent immunosuppressive factors released by gliomas6 PPAR Research
allowing glioma cells to escape from immune surveillance
[34, 35]. Friese et al. [24] demonstrated that combined TGF-
β1 and TGF-β2 knock down in human LNT-229 glioma
cells results in a loss of tumorigenicity when xenografted
into CD1 nude mice, and natural killer cells isolated from
these animals show an activated phenotype. More than 10
years ago, St¨ ander et al. [36] have shown that inhibition
of TGF-β signaling by decorin increases the number of B
and T cells (CD45+), T helper cells (CD4+), cytotoxic T
cells (CD8+), and, most prominently, of activated T cells
(CD25+) inﬁltrating the tumor in an intracerebral C6 rat
glioma model. By employing an SMA-560 mouse glioma
model, Tran et al. [37] have shown that inhibition of TGF-β
signaling by the TGF-β RI kinase inhibitor SX-007 increased
T-cell(CD3+)inﬁltrationintothetumor.Duetothefactthat
inhibition of TGF-β signaling has been shown to enhance
antiglioma immune responses in vivo [24, 36, 37]i ta p p e a r s
likely that troglitazone, inhibiting TGF-β1 release at clinically
achievable doses [9, 38], restores immune surveillance.
However, the yet-unknown protein/proteins mediating the
inhibition of glioma progression by troglitazone and Δ2-
troglitazone remain(s) to be identiﬁed and may represent
future targets for structure-relationship studies. Moreover,
PPARγ inactive derivatives of known PPARγ agonists which
retain their propensity to counteract glioma progression
might be further developed to minimize potential PPARγ
mediated side eﬀects in glioma patients.
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